2. UroToday Home
  3. Video Lectures

CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?)

Welcome and Background Cancer or Not Cancer "Presentation" - Scott Eggener
July 24, 2024
Details
Rationale for Nomenclature Change Gleason Grade 1 Cancer "Presentation" - Matthew Cooperberg
July 24, 2024
Details
Reservations About a Nomenclature Change for Gleason Grade 1 Prostate Cancer "Presentation" - Adam Kibel
July 24, 2024
Details
What is in a Name? Inadvertent Harm from the Designation and Label of 'Cancer' "Presentation" - Laura Esserman
July 24, 2024
Details
Grade Group 1 Prostate Cancer: A Pathologist's Case for Cancer Classification 'Con' "Presentation" - Gladell Paner
July 24, 2024
Details
Grade Group 1 Prostate Cancer: A Pathologist's Case for Cancer Classification 'Pro' "Presentation" - Theodorus van der Kwast
July 24, 2024
Details
Prostate Cancer Classification Dilemma: Lessons from Breast and Colorectal Tumors "Presentation" - Jeffry Simko
July 24, 2024
Details
Prostate Cancer Biopsy Sampling: Challenges in Grade Group 1 Classification "Discussion" - Lawrence True
July 24, 2024
Details
Rethinking Cancer Treatment: Lessons from Breast to Prostate Cancer "Presentation" - Alastair Lamb
July 24, 2024
Details
Where to Draw the Line? The Spatial Molecular Continuum from 'Normal' to GG1 to GG2 Prostate Cancer "Presentation" - Alastair Lamb
July 24, 2024
Details
Active Surveillance in Prostate Cancer: Rethinking Gleason Grade Group 1 "Presentation" - Daniel Lin
July 24, 2024
Details
Active Surveillance Challenges in Prostate Cancer Management "Presentation" - Laurence Klotz
July 24, 2024
Details
MRI Impact on Grade Group 1 Prostate Cancer Detection in Australia "Presentation" - Declan Murphy
July 24, 2024
Details
Active Surveillance vs. Watchful Waiting in Prostate Cancer Management "Presentation" - Caroline Moore
July 24, 2024
Details
Prostate Cancer Risk Assessment: Beyond Gleason Pattern Ratios "Presentation" - Andrew Vickers
July 24, 2024
Details
Modeling Prostate Cancer: Rethinking Grade Group 1 Classification "Presentation" - Ruth Etzioni
July 24, 2024
Details
The Debate on Prostate Cancer Grading: Addressing Underdiagnosis and Overdiagnosis Concerns "Presentation" - Andrew Vickers
July 24, 2024
Details
Rethinking Prostate Cancer Classification: The Cribriform Pattern Debate "Discussion"
July 24, 2024
Details
Alternative Payment Models in Prostate Cancer: Nomenclature Impact "Presentation" - CJ Stimpson
July 24, 2024
Details
Active Surveillance in Europe: Challenges and Heterogeneity "Presentation" - Derya Tilki
July 24, 2024
Details
Prostate Cancer in Africa: Pathology Outcomes and Risk Profiles "Presentation" - Mohamed Jalloh
July 24, 2024
Details
Prostate Cancer Diagnosis: MRI vs. Systematic Biopsy "Discussion"
July 24, 2024
Details
Racial Disparities in Prostate Cancer Active Surveillance Outcomes "Presentation" - Quoc-Dien Trinh
July 24, 2024
Details
Prostate Cancer Risk Assessment: Addressing Racial Equity Concerns "Discussion"
July 24, 2024
Details
Renaming Gleason 6 Prostate Cancer: Patient Perspectives and Impacts "Presentation" - Howard Wolinsky
July 24, 2024
Details
Patient Perspectives on Prostate Cancer: Quality of Life and Treatment Decisions "Presentation" - Leszek Izdebski
July 24, 2024
Details
CDC's Role in Advancing Prostate Cancer Active Surveillance Research "Presentation" - Ingrid Hall
July 24, 2024
Details
Prostate Cancer Nomenclature: Impact on Screening Guidelines "Presentation" - Timothy Wilt
July 24, 2024
Details
Rethinking Grade Group 1 Prostate Cancer: UK's Paradigm Shift "Presentation" - Hashim Ahmed
July 24, 2024
Details
Rethinking Prostate Cancer Diagnosis: UK vs US Approaches "Discussion"
July 24, 2024
Details
Prostate Cancer Markers: Challenges in Differentiating Low-Risk Cases "Discussion"
July 24, 2024
Details
Genomics in Prostate Cancer: Limitations in Active Surveillance "Presentation" - Felix Feng
July 24, 2024
Details
Redefining Prostate Cancer: The Debate on Grade Group 1 Classification "Discussion"
July 24, 2024
Details
Reclassifying Prostate Cancer: Clinical Implications of Grade Group 1 Nomenclature Change "Discussion"
July 24, 2024
Details
Prostate Cancer Nomenclature Change: Impact on Advocacy and Patient Care "Discussion"
July 24, 2024
Details
Prostate Cancer Nomenclature Change: Societal and Clinical Implications "Discussion"
July 24, 2024
Details
Prostate Cancer Management: Rethinking Active Surveillance and Nomenclature "Discussion"
July 24, 2024
Details
Exploring Financial Toxicity and Cultural Differences in Prostate Cancer Active Surveillance "Discussion"
July 22, 2024
Details